跳到正文
原文
STAT Pharma 医药频道· Ed Silverman·· 2026-09-30AI 评分46

多名国会议员敦促特朗普政府重新考虑限制从加拿大和海外进口药品的新规

STAT+: Lawmakers urge Trump to rethink new rule that could restrict imported meds from Canada and overseas

AI 导读

越来越多的国会议员敦促特朗普政府重新考虑一项将于下月生效的联邦新规,该规定可能阻止美国人从合法的国际药房获取处方药。拟议规则要求从海外邮寄的药品必须经过强制要求持牌报关行和提交入境保证金的关税程序。

正文

By Ed Silverman

Sept. 29, 2026

Pharmalot Columnist, Senior Writer

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter and the afternoon Pharmalot newsletter.

A growing number of congressional lawmakers are urging the Trump administration to rethink a federal rule going into effect next month over concerns it will prevent Americans from obtaining prescription medicines from licensed international pharmacies.

The pending rule requires medicines mailed from abroad to go through a customs process that mandates a licensed customs broker and a financial guarantee in the form of an entry bond. This is an added burden — and cost — for Americans who, for years, have been able to receive prescriptions from Canada and other countries with relatively little difficulty as they sought to save money on expensive drugs.

Indeed, the clamor for imports began two decades ago as prices rose, prompting some Americans to take bus rides to Canada. Under current law, though, it is illegal to import a medicine into the U.S. for personal use under most circumstances because the drugs often have not been approved by the Food and Drug Administration as safe and effective.

STAT+ Exclusive Story

Already have an account? Log in

STAT+

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

来源:STAT Pharma 医药频道 · statnews.com